Using decision theory for precise choice of breast cancer treatment
The precise choice of treatment for breast cancer depends upon the status of the hormone receptors (for estrogen and progesterone). Their conventional determination by means of immunohistochemistry (IHC) is associated with a certain error rate, which can be reduced by adding genomic data.
Even conventional statistics can bring about a notable improvement but now it is possible to use decision theory to optimally combine diagnostic findings, particularly where they are contradictory.
This is the finding of a recent study conducted by MedUni Vienna under the leadership of Wolfgang Schreiner from the Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS).
The Pap smear â the most important screening tool for cervical cancer. While obtaining this test may be temporarily uncomfortable during your routine gynecologic wellness exam, the âPapâ serves a crucial role in keeping patients healthy. From 1955 to 1992, the routine use of Pap testing reduced the mortality rate of cervical cancer by 70%, and with consistent use of this tool, earlier detection is possible with a continued decreased rate of death.
Even with these great strides in cervical cancer detection, this cancer remains more common and more deadly in nonwhite populations. Incidence of cervical cancer is up to 35% higher in Hispanic and non-Hispanic Black populations than the non-Hispanic white population. The Pap test helps to equalize health outcomes, and the ease with which it is performed (a simple, in-office test) means that it can be widely used across all health clinics.
I am afraid. When vaccines rolled out in Virginia this region’s citizens lined up. Southwest Virginia’s vaccination rate is higher than Virginia and the nation’s over all.
Crizotinib (Xalkori) has approval as first-line therapy for
ROS1 fusion-positive metastatic NSCLC but has poor CNS penetration, the authors noted, adding that in about half of patients treated with crizotinib, initial progression occurs only in the CNS.
Entrectinib is designed to cross the blood-brain barrier, and preclinical studies showed that the agent achieves high CNS concentrations, which were associated with strong efficacy in brain-tumor models.
Integrated Analysis
For the analysis, the investigators evaluated entrectinib in three phase I or II clinical trials of patients with locally advanced or metastatic
ROS1 fusion-positive NSCLC. A preliminary analysis of a 53-patient efficacy-evaluable population showed a 77% objective response rate (ORR) and a median duration of response (DoR) of 24.6 months.
Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate.